KMT2A and acute myeloid leukemia: In their study, Kumar B. et al., treated MLL-rearranged AML cells expressing MLL-AF9 with artesunate and confirmed its cytotoxic activity in vitro and in vivo as well as its synergy with the BCL-2 inhibitor venetoclax.